论文部分内容阅读
钙拮抗剂治疗高血压病已取得较大进展。国内对硝苯吡啶的报道,近年亦明显增多,但有关异搏停的降压效应观察尚少。现将我们对异搏停、硝苯吡啶及硝苯吡啶加心得安的临床观察结果报告如下。临床资料一、治疗对象按世界卫生组织高血压病诊断标准选择50例患者,男性32例,女性18例,年龄为30～70岁(53.7±8.6),病程为0.5～20年,大部分人在10年左右。患者均经询问病史、体检及临床有关检查,以除外继发性高血压症。患者按世界卫生组织高血压病分期:Ⅰ期3人;Ⅱ期44人;Ⅲ期3人。
Calcium antagonists have made great progress in the treatment of hypertension. Domestic reports of nifedipine, also significantly increased in recent years, but the antihypertensive effect of verapamil observed less. Now we are on the verapamil, nifedipine and nifedipine plus propranolol clinical observations are reported below. Clinical data First, the treatment of patients according to WHO diagnostic criteria for hypertension 50 patients selected, 32 males and 18 females, aged 30 to 70 years (53.7 ± 8.6), duration of 0.5 to 20 years, most people In about 10 years. Patients were asked history, physical examination and clinical examination, with the exception of secondary hypertension. Patients according to WHO staging of hypertension: Ⅰ phase 3; Ⅱ phase 44; Ⅲ phase 3.